SSA
CLVS

Schonfeld Strategic Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,300
Closed -$28K – 3086
2021
Q4 		$28K Buy
+10,300
New +$38.1K ﹤0.01% 1971
2021
Q2 		– Sell
-25,807
Closed -$181K – 2474
2021
Q1 		$181K Buy
+25,807
New +$173K ﹤0.01% 1540
2020
Q4 		– Sell
-267,646
Closed -$1.56M – 1973
2020
Q3 		$1.56M Buy
+267,646
New +$1.6M 0.03% 584
2020
Q2 		– Sell
-14,585
Closed -$93K – 1628
2020
Q1 		$93K Buy
+14,585
New +$117K 0.01% 1011
2018
Q1 		– Sell
-69,240
Closed -$4.71M – 1032
2017
Q4 		$4.71M Buy
69,240
+23,176
+50% +$1.62M 0.39% 75
2017
Q3 		$3.8M Sell
46,064
-64,593
-58% -$5.12M 0.35% 93
2017
Q2 		$10.4M Buy
110,657
+65,939
+147% +$4.03M 1.07% 9
2017
Q1 		$2.85M Buy
44,718
+7,844
+21% +$477K 0.29% 104
2016
Q4 		$1.64M Sell
36,874
-109,448
-75% -$3.85M 0.21% 139
2016
Q3 		$5.28M Buy
146,322
+121,882
+499% +$2.62M 0.9% 25
2016
Q2 		$336K Buy
24,440
+12,344
+102% +$180K 0.08% 291
2016
Q1 		$233K Buy
+12,096
New +$256K 0.1% 256

Other funds holding CLVS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Schonfeld Strategic Advisors's CLVS Position: Q1 2022 in Review

Schonfeld Strategic Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q1 2022, closing a stake of 10,300 shares — an estimated $28K sold.

Schonfeld Strategic Advisors first reported a position in CLVS in Q1 2016 and held it in 12 quarters. The position peaked at $10.4M in Q2 2017. 153 funds tracked by Wall St. Rank hold CLVS as of Q1 2022.

  • Schonfeld Strategic Advisors reported no remaining Clovis Oncology, Inc. position as of Q1 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 10,300 Clovis Oncology, Inc. shares in Q1 2022, an estimated $28K.
  • Schonfeld Strategic Advisors first reported a position in Clovis Oncology, Inc. in Q1 2016 and held it in 12 quarters.
  • Schonfeld Strategic Advisors's Clovis Oncology, Inc. position peaked at $10.4M in Q2 2017.
  • 153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2022, filed 16 May 2022.